Apoxis, Topotarget deal
TOPO will acquire Apoxis for E14.5 million ($19.4 million) in stock. Apoxis’ shareholders will provide Apoxis with a E4 million ($5.3 million) convertible loan prior to the deal’s close and will be eligible for more than E10 million ($13.4 million) in milestones. Apoxis’ APO866 is in Phase II trials to treat advanced melanoma and cutaneous T cell lymphoma (CTCL) and Phase I/II trials to treat refractory B-chronic lymphocytic leukemia (CLL). The nicotinamide phosphoribosyl transferase (NMPRT) inhibitor is licensed from Astellas Pharma Inc. (Tokyo:4503, Tokyo, Japan). APO010, a recombinant human Fas ligand, is in Phase I testing to treat advanced cancers. TOPO expects to out-license or sell Apoxis’ APO200, a recombinant human protein in preclinical development to treat hypohidrotic ectodermal dysplasia, and Inflammasome, an IP portfolio covering an undisclosed inflammatory signaling pathway. ...